ERBB2 and neoplasm: Higher doses of DZD1516 led to higher exposure in plasma and concurrent more profound inhibition of pHER2 in tumor xenograft tissue, suggesting a positive correlation between drug exposure and pHER2 inhibition in the HER2+ xenograft model (Fig. 4).